Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response
Compose a Response to This Article
Other responses
No responses have been published for this article.
